Lung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Int J Chron Obstruct Pulmon Dis. 2019 Aug 7;14:1779-1787. doi: 10.2147/COPD.S162781. eCollection 2019.
Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also possible that this subgroup may benefit from biologic treatments targeting eosinophilic inflammation. Mepolizumab, a humanized monoclonal antibody against interleukin-5 (IL-5), may have a therapeutic effect in a subgroup of patients with COPD and eosinophilic airway inflammation. In this review, we discuss the biologic rationale for mepolizumab targeting IL-5 in eosinophilic COPD as well as the results of recently published clinical trials.
尽管进行了最大程度的医学治疗，但仍有一部分慢性阻塞性肺疾病患者持续遭受急性加重。此外，这部分人群中还有一部分人血液中的嗜酸性粒细胞升高。除了对吸入性皮质类固醇反应更好之外，这一亚组可能还受益于针对嗜酸性粒细胞炎症的生物治疗。美泊利单抗是一种针对白细胞介素-5（IL-5）的人源化单克隆抗体，可能对 COPD 和嗜酸性气道炎症患者亚组具有治疗作用。在这篇综述中，我们讨论了美泊利单抗针对嗜酸性 COPD 中的 IL-5 的生物学原理以及最近发表的临床试验结果。
